DANVERS, Mass.--(BUSINESS WIRE)--Abiomed, Inc. (NASDAQ: ABMD), a leading provider of break-through heart support technologies, today announced the successful first human use of the Impella cVADTM device, a new, percutaneous Impella heart pump that provides peak flow of approximately 4 liters of blood per minute. The Impella cVAD is designed to provide temporary circulatory support and reduce the workload of the heart muscle via a minimally invasive, catheter-based pump that is inserted percutaneously in the cardiac catheterization lab, without the need for surgical intervention.
